Biopharmaceutical Scientists specialize in the development and production of biologically-based medicines, including therapeutic proteins, antibodies, and vaccines, derived from living organisms. Their work involves understanding the molecular mechanisms of diseases and designing biologics that can interact with the body to treat or prevent them. These scientists work with complex biologic molecules, ensuring they are stable, effective, and safe for human use. From early-stage discovery to large-scale manufacturing, biopharmaceutical scientists employ advanced techniques like recombinant DNA technology, cell culture, and protein engineering to develop new treatments. Their expertise is essential in the development of innovative therapies for conditions that are difficult to treat with traditional pharmaceuticals, such as autoimmune diseases and cancer.
Biopharmaceutical scientists are also responsible for optimizing production processes and ensuring regulatory compliance. They collaborate with regulatory agencies, quality control teams, and manufacturing experts to scale up production and ensure that products meet strict safety and efficacy standards. As biologic therapies become increasingly common, these scientists are pushing the boundaries of medicine by developing personalized and targeted treatments that offer more precise and effective solutions for patients. Their research continues to be pivotal in shaping the future of healthcare, offering hope for patients with conditions that previously had limited treatment options. With the rise of biologics, biopharmaceutical scientists are at the forefront of modern medicine, driving breakthroughs that will impact global healthcare for years to come.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation